Economic Burden of RSV-Associated Hospitalizations in Switzerland: A Nationwide Analysis (2017–2023)

Maria Boesing, Daphne McCarthy-Pontier, Joerg Daniel Leuppi, Nike Julia Kräutler · 2026

Read Economic Burden of RSV-Associated Hospitalizations in Switzerland: A Nationwide Analysis (2017–2023) by Maria Boesing, Daphne McCarthy-Pontier, Joerg Daniel Leuppi, Nike Julia Kräutler (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13300369.txt.

Description

Hospital stays for respiratory syncytial virus cost Switzerland tens of millions of francs each year, Maria Boesing and colleagues calculate in a 2026 nationwide analysis. Using federal hospitalization records from 2017 to 2023 plus SwissDRG cost data, they priced RSV admissions by age group and adjusted for the longer stays these patients need.

Total inpatient costs came to roughly CHF 55.1 to 76.0 million per year. Children under ten filled the most beds and drew the largest share of the bill. Adults over sixty cost nearly as much in total, because each case ran longer and more severe. The figures give prevention programs and vaccine payment decisions a firmer economic footing.

Catalog record

CREATORMaria Boesing, Daphne McCarthy-Pontier, Joerg Daniel Leuppi, Nike Julia Kräutler
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE27177
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13300369

Browse the full library · About the Tower of Babel